Meningioma recurrence

Open Medicine

Klekner Álmos¹  Varkoly Gréta²  Bencze János²  Kouhsari Mahan C²  Hortobágyi Tibor³ 

[1] Department of Neurosurgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;Division of Neuropathology, Institute of Pathology, University of Debrecen, Debrecen, Hungary;Division of Neuropathology, Institute of Pathology, University of Debrecen, Debrecen, Nagyerdei krt. 98., H-4032, Hungary;

关键词: genetics;    immunohistochemistry;    meningioma;    molecular biology;    neuropathology;    pathology;    prognostic factors;    recurrence;   

DOI  :  10.1515/med-2016-0032

来源: DOAJ

【 摘 要 】

Meningioma accounts for more than 30% of all intracranial tumours. It affects mainly the elderly above the age of 60, at a female:male ratio of 3:2. The prognosis is variable: it is usually favourable with no progression in tumour grade and no recurrence in WHO grade 1 tumours. However, a minority of tumours represent atypical (grade 2) or anaplastic (grade 3) meningiomas; this heterogeneity is also reflected in histopathological appearances. Irrespective of the grade, the size of the tumour and the localisation may have severe, sometimes lethal consequences. Following neurosurgical interventions to remove the tumour, recurrence and progression in WHO grade may occur. Our knowledge on predisposing histomorphological and molecular factors of recurrence is rather limited. These can be classified as I) demographic II) environmental, III) genetic and epigenetic IV) imaging, V) neuropathological, and VI) neurosurgical. In view of the complex background of tumour recurrence, the recognition of often subtle signs of increased risk of recurrence requires close collaboration of experts from several medical specialties. This multidisciplinary approach results in better therapy and fewer complications related to tumour recurrence.

【 授权许可】

Unknown